“Biological medicines have revolutionised patient treatment by offering new and effective medicines for acute and chronic conditions including neutropenia, cancer, a wide range of inflammatory and autoimmune diseases, and enzyme or hormone deficiencies. As the patent expires for individual originator medicines, biosimilar medicines can be introduced to provide additional options for patients and the NHS.
Biosimilar medicines have been used in the NHS for many years as treatments for growth hormone replacement, neutropenia and anaemia related to chronic renal failure or cancer.
A biosimilar medicine is a biological medicine which is highly similar to another biological medicine already licensed for use. It is a biological medicine
which has been shown not to have any clinically meaningful differences from the originator biological medicine in terms of quality, safety and efficacy.
Biosimilar medicines are not considered generic equivalents to their originator biological medicine because the two products are similar but not identical.
However, they will have met regulatory requirements in terms of comparative quality, safety and efficacy.”
Thanks to NHS England for the above text.
For more information see
UK members - Act now to stop the proposed withdrawal of vital COVID medicines!
Stress Exacerbates CLL And Speeds Up Its Progression
Bloodwise news
